Repligen (NASDAQ:RGEN) Coverage Initiated at Wolfe Research

Analysts at Wolfe Research assumed coverage on shares of Repligen (NASDAQ:RGEN) in a research report issued to clients and investors on Thursday, MarketBeat reports. The brokerage set a “peer perform” rating on the biotechnology company’s stock.

Several other research analysts also recently weighed in on RGEN. Wells Fargo & Company began coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 target price for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday. UBS Group dropped their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Finally, JPMorgan Chase & Co. upped their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Repligen presently has a consensus rating of “Moderate Buy” and an average price target of $190.25.

Repligen Price Performance

Repligen stock opened at $124.73 on Thursday. The firm’s 50-day simple moving average is $141.54 and its 200 day simple moving average is $144.77. Repligen has a 52 week low of $113.50 and a 52 week high of $211.13. The firm has a market capitalization of $6.99 billion, a PE ratio of -337.10, a P/E/G ratio of 4.36 and a beta of 0.96. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The firm had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same quarter in the previous year, the company posted $0.23 EPS. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. On average, equities research analysts predict that Repligen will post 1.44 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company’s stock.

Institutional Trading of Repligen

A number of institutional investors and hedge funds have recently bought and sold shares of RGEN. Andra AP fonden acquired a new stake in Repligen during the 2nd quarter worth approximately $25,000. International Assets Investment Management LLC purchased a new position in Repligen in the 2nd quarter worth approximately $33,000. UMB Bank n.a. boosted its holdings in Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 130 shares during the period. Lazard Asset Management LLC boosted its holdings in Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 136 shares during the period. Finally, Blue Trust Inc. boosted its holdings in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 127 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.